NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: N-methyl-D-aspartate receptors are one member of a family of ionotropic glutamate receptors that play a pivotal role in synaptic plasticity processes associated with learning and have become attractive therapeutic targets for diseases such as depression, anxiety, schizophrenia, and neuropathic pain. NYX-2925 ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide) is one member of a spiro-β-lactam-based chemical platform that mimics some of the dipyrrolidine structural features of rapastinel (formerly GLYX-13: threonine-proline-proline-threonine) and is distinct from known N-methyl-D-aspartate receptor agonists or antagonists such as D-cycloserine, ketamine, MK-801, kynurenic acid, or ifenprodil. Methods: The in vitro and in vivo pharmacological properties of NYX-2925 were examined. Results: NYX-2925 has a low potential for "off-target" activity, as it did not exhibit any significant affinity for a large panel of neuroactive receptors, including hERG receptors. NYX-2925 increased MK-801 binding to human N-methyl-D-aspartate receptor NR2A-D subtypes expressed in HEK cells and enhanced N-methyl-D-aspartate receptor current and long-term potentiation (LTP) in rat hippocampal slices (100-500 nM). Single dose ex vivo studies showed increased metaplasticity in a hippocampal LTP paradigm and structural plasticity 24 hours after administration (1 mg/kg p.o.). Significant learning enhancement in both novel object recognition and positive emotional learning paradigms were observed (0.01-1 mg/kg p.o.), and these effects were blocked by the N-methyl-D-aspartate receptor antagonist CPP. NYX-2925 does not show any addictive or sedative/ataxic side effects and has a therapeutic index of >1000. NYX-2925 (1 mg/kg p.o.) has a cerebrospinal fluid half-life of 1.2 hours with a Cmax of 44 nM at 1 hour. Conclusions: NYX-2925, like rapastinel, activates an NMDA receptor-mediated synaptic plasticity process and may have therapeutic potential for a variety of NMDA receptor-mediated central nervous system disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 1×
“N-methyl-D-aspartate (NMDA) receptors are one of a family of ligand gated ionotropic glutamate receptors that are found predominantly in the CNS and developmentally regulated (CullCandy et al., 2001; Traynelis et al., 2010).”
BackgroundNMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523 · cited 1×
“They are heterotetrameric complexes that are expressed as multiple subtypes each with unique properties (Paoletti et al., 2013).”
BackgroundStructural basis of long-term potentiation in single dendritic spines
Matsuzaki, M., Honkura, N., Ellis-Davies, G. C. R., & Kasai, H. (2004) · Nature · doi:10.1038/nature02617 · Cited by 2,483 · cited 10×
“LTP was measured 40 minutes after the last high-frequency bout of stimulation.”
BackgroundInfluentialNMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
Spine-Neck Geometry Determines NMDA Receptor-Dependent Ca2+ Signaling in Dendrites
Noguchi, J., Matsuzaki, M., Ellis-Davies, G. C. R., & Kasai, H. (2005) · Neuron · doi:10.1016/j.neuron.2005.03.015 · Cited by 419
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339 · cited 2×
“Clinical trial data have shown that NMDA receptor modulators have efficacy in mood disorders such as depression, obsessive compulsive disorder, schizophrenia, as well as in neuropathic pain, among others (Rodriguez et al., 2013; Cain et al., 2014; Feder et al., 2014; Fond et al., 2014; Maher et al., 2017).”
BackgroundNMDA receptors and memory encoding
Morris, R. G. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.014 · Cited by 295 · cited 2×
“…including activity-dependent synaptic plasticity associated with learning and memory (Bliss and Collingridge, 1993; Yashiro and Philpot, 2008; Morris, 2013) and have been implicated in a variety of CNS disorders, including schizophrenia (Coyle, 2012; Goff, 2012), mood disorders (Ghasemi…”
BackgroundBurgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Self-citation
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Current and Emerging Pharmacotherapy for Fibromyalgia
Tzadok, R., & Ablin, J. N. (2020) · Pain Research and Management · doi:10.1155/2020/6541798 · Cited by 122
“+is finding led to the hypothesis that it would be effective in NMDA receptorassociated CNS disorders [83].”
BackgroundZanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-22.2022 · Cited by 115
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
Metadata
- Authors
- Khan, M. A., Houck, D. R., Gross, A. L., Zhang, X.-L., Cearley, C., Madsen, T. M., Kroes, R. A., Stanton, P. K., Burgdorf, J., & Moskal, J. R.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-01
- Volume
- 21
- Issue
- 3
- Pages
- 242-254
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2774515581
- Cited by
- 55
- References
- 17
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. https://app.cochat.ai/papers/10.1093/ijnp/pyx096
- The paper
- Khan, M. A., Houck, D. R., Gross, A. L., Zhang, X.-L., Cearley, C., Madsen, T. M., Kroes, R. A., Stanton, P. K., Burgdorf, J., & Moskal, J. R. (2018). NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyx096
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.